<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689778</url>
  </required_header>
  <id_info>
    <org_study_id>1497</org_study_id>
    <nct_id>NCT02689778</nct_id>
  </id_info>
  <brief_title>Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy</brief_title>
  <official_title>Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grupo Medifarma, S. A. de C. V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is estimated that approximately 30% of patients with diabetes develop diabetic
      nephropathy. Diabetic nephropathy is a multifactorial progressive disease that occurs through
      various mechanisms such as hyperglycemia, oxidative stress, inflammation and fibrosis,
      control or blocking these mechanisms are therefore potential therapeutical targets for this
      entity. Current treatment options are based on the glycemic control, blood pressure control,
      as well as the use of medications such as angiotensin-converting enzyme inhibitors and
      Angiotensin II receptor antagonists, these actions are not enough to stop progression.
      Pirfenidone is a drug with antifibrotic, antioxidant, and anti-inflammatory properties.
      Although the specific mechanism is unknown, pirfenidone interferes with the expression,
      secretion and the effect of the β (TGF-β) transforming growth factor. The investigators plan
      to carry out a controlled clinical study to evaluate the effect of pirfenidone in patients
      with type 2 diabetes and nephropathy. The period of time the treatment will be administered
      will be of 12 months, 62 patients will be included. The primary outcome will be improvement
      in glomerular filtration rate. The secondary outcomes will be number of patients requiring
      replacement therapy, 24 hour urine microalbuminuria and change in the concentration of TGF -
      β. Change in these parameters will be evaluated at the end of the treatment period (12
      months). Throughout the study the incidence of adverse events will be recorded, wich will
      allow us to learn about the safety and security of the drug in this population.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of oral pirfenidone (1800 mg) in albuminuria</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of oral pirfenidone (1800 mg) in glomerular filtration rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>hypersensitivity, photosensitivity, liver function test alteration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <condition>Albuminuria</condition>
  <arm_group>
    <arm_group_label>Pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral pirfenidone 600 mg with breakfast and 1200 mg with dinner for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo with breakfast and with dinner for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.</description>
    <arm_group_label>Pirfenidone</arm_group_label>
    <other_name>Kitoscell LP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical tablets without active substance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Body mass index (BMI) less than 35 kg/m2

          -  Diagnosis of diabetes mellitus type 2

          -  Glomerular filtration rate of 15-89 ml/min

          -  Albuminuria ≥30 mg/24 h and &lt; 3.5 g/24 h

          -  Individuals with blood pressure less than 140/90 mmHg or treated with stable doses of
             anti-hypertensive drugs.

          -  Glycated hemoglobin &lt;10%

        Exclusion criteria

          -  Another etiology of renal disease (autoimmune diseases, polycystic kidney disease)

          -  Repeated urinary tract infections (more than three episodes in the past year)

          -  Photosensitivity to any drug

          -  Liver disease

          -  Pregnancy

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ)</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pirfenidone</keyword>
  <keyword>Diabetic nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

